clinical trial · NCT06682728
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
University of California, Irvine·phase2·recruiting·n = 23
Urothelial CarcinomaMuscle-invasive Bladder CancerSacituzumab Govitecan (SG)Nivolumab
brief summary
This is a phase 2 study, single-arm study of adjuvant combination therapy with Sacituzumab Govitecan and Nivolumab in patients with muscle-invasive urothelial carcinoma of the bladder, ureter, or upper tract, who are high risk for cancer recurrence post curative-intent surgery based on surgical pathology.
started
Nov 15, 2024
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Apr 30, 2026
official title
Adjuvant Sacituzumab Govitecan Plus Nivolumab in Patients With Muscle-Invasive Urothelial Carcinoma at High-Risk for Recurrence
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol